Jennifer Cautela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7796000/publications.pdf

Version: 2024-02-01

687363 642732 1,055 25 13 23 citations h-index g-index papers 25 25 25 1442 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor–induced Myocarditis. Radiology, 2022, 303, 512-521. | 7.3 | 21 |
| 2 | Cancer Therapies and Vascular Toxicities. Current Treatment Options in Oncology, 2022, 23, 333-347. | 3.0 | 6 |
| 3 | Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 312-320. | 3.0 | 42 |
| 4 | Management of Immune Checkpoint Inhibitor–Induced Myocarditis. JACC: CardioOncology, 2021, 3, 157-161. | 4.0 | 22 |
| 5 | Rational and Design of the SIMULATOR Study: A Multicentre Randomized Study to Assess the Impact of SIMULation-bAsed Training on Transoesophageal echocardiOgraphy leaRning for Cardiology Residents. Frontiers in Cardiovascular Medicine, 2021, 8, 661355. | 2.4 | 3 |
| 6 | Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis. JAMA Cardiology, 2021, 6, 1329. | 6.1 | 64 |
| 7 | Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. Canadian Journal of Cardiology, 2020, 36, 476-481. | 1.7 | 40 |
| 8 | Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardioâ€Oncology Guidelines. Journal of the American Heart Association, 2020, 9, e018403. | 3.7 | 149 |
| 9 | Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis., 2020, 8, e001887. | | 45 |
| 10 | Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients. European Journal of Internal Medicine, 2019, 68, 71-75. | 2.2 | 16 |
| 11 | Dynamic iron status after acute heart failure. Archives of Cardiovascular Diseases, 2019, 112, 410-419. | 1.6 | 5 |
| 12 | Device-Related Thrombus After Left Atrial Appendage Occlusion With the Amulet Device. Heart Lung and Circulation, 2019, 28, 1683-1688. | 0.4 | 4 |
| 13 | Impact of the time-to-treatment concept on the outcome of acute heart failure: A pilot study. Archives of Cardiovascular Diseases, 2018, 111, 270-275. | 1.6 | 3 |
| 14 | Response to the letter: The high burden of coronary artery disease in heart failure with preserved ejection fraction. Archives of Cardiovascular Diseases, 2018, 111, 227. | 1.6 | 1 |
| 15 | Takotsubo-Like Syndrome in CancerÂPatients Treated With ImmuneÂCheckpoint Inhibitors. JACC: Cardiovascular Imaging, 2018, 11, 1187-1190. | 5.3 | 82 |
| 16 | Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach. Archives of Cardiovascular Diseases, 2018, 111, 109-118. | 1.6 | 23 |
| 17 | Ventricular Arrhythmia Occurrence and Compliance in Patients Treated With the Wearable Cardioverter Defibrillator Following Percutaneous Coronary Intervention. Heart Lung and Circulation, 2018, 27, 984-988. | 0.4 | 7 |
| 18 | Response by Thuny et al to Letter Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity― Circulation, 2018, 137, 2423-2424. | 1.6 | 0 |

| # | Article | IF | CITATION |
|----|---|-----|----------|
| 19 | Controlled sedation with midazolam and analgesia with nalbuphine to alleviate pain in patients undergoing subcutaneous implantable cardioverter defibrillator implantation. Journal of Interventional Cardiac Electrophysiology, 2017, 49, 191-196. | 1.3 | 14 |
| 20 | Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. International Journal of Cardiology, 2017, 241, 387-392. | 1.7 | 27 |
| 21 | Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity. Circulation, 2017, 136, 2085-2087. | 1.6 | 364 |
| 22 | Prehospital and in-hospital course of care for patients with acute heart failure: Features and impact on prognosis in "real lifeâ€. Archives of Cardiovascular Diseases, 2017, 110, 72-81. | 1.6 | 5 |
| 23 | Wearable cardioverter defibrillator: Bridge or alternative to implantation?. World Journal of Cardiology, 2017, 9, 531. | 1.5 | 11 |
| 24 | Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. International Journal of Cardiology, 2016, 224, 366-375. | 1.7 | 32 |
| 25 | Etiology of Pericarditis in a Prospective Cohort of 1162 Cases. American Journal of Medicine, 2015, 128, 784.e1-784.e8. | 1.5 | 69 |